152 related articles for article (PubMed ID: 30129511)
21. Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016.
Alexander GC; Ogasawara K; Wiegand D; Lin D; Breder CD
Ther Innov Regul Sci; 2019 Nov; 53(6):752-758. PubMed ID: 30509142
[TBL] [Abstract][Full Text] [Related]
22. Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases.
DiMasi JA; Florez MI; Stergiopoulos S; Peña Y; Smith Z; Wilkinson M; Getz KA
Clin Pharmacol Ther; 2020 Feb; 107(2):324-332. PubMed ID: 31502248
[TBL] [Abstract][Full Text] [Related]
23. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
[TBL] [Abstract][Full Text] [Related]
24. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
[TBL] [Abstract][Full Text] [Related]
25. 2014 in review: FDA approval of new drugs.
Kinch MS
Drug Discov Today; 2017 Apr; 22(4):620-624. PubMed ID: 26100738
[TBL] [Abstract][Full Text] [Related]
26. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
Miller JE; Korn D; Ross JS
BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
[TBL] [Abstract][Full Text] [Related]
27. Sex or Gender Reporting in Ophthalmology Clinical Trials Among US Food and Drug Administration Approvals, 1995 to 2022.
Xie JS; Kaur H; Tao B; Lee J; Solish D; Kohly R; Margolin E
JAMA Ophthalmol; 2024 Feb; 142(2):123-130. PubMed ID: 38236588
[TBL] [Abstract][Full Text] [Related]
28. Racial representation in clinical trials for dermatological new molecular entities.
Ha MV; Wong C
Clin Exp Dermatol; 2022 Feb; 47(2):386-388. PubMed ID: 34346107
[TBL] [Abstract][Full Text] [Related]
29. Tracking inclusion of women in clinical studies.
Wood SF
J Womens Health (Larchmt); 2009 Mar; 18(3):301-2. PubMed ID: 19231989
[No Abstract] [Full Text] [Related]
30. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
[TBL] [Abstract][Full Text] [Related]
31. [Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].
Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):80-2. PubMed ID: 17405529
[TBL] [Abstract][Full Text] [Related]
32. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
[TBL] [Abstract][Full Text] [Related]
33. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
34. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.
Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I
Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199
[TBL] [Abstract][Full Text] [Related]
35. 2016 in review: FDA approvals of new molecular entities.
Griesenauer RH; Kinch MS
Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
[TBL] [Abstract][Full Text] [Related]
36. Patent life of antiretroviral drugs approved in the US from 1987 to 2007.
Rodriguez-Monguio R; Seoane-Vazquez E
AIDS Care; 2009 Jun; 21(6):760-8. PubMed ID: 19499381
[TBL] [Abstract][Full Text] [Related]
37. Racial and Ethnic Differences in Drug Disposition and Response: Review of New Molecular Entities Approved Between 2014 and 2019.
Ramamoorthy A; Kim HH; Shah-Williams E; Zhang L
J Clin Pharmacol; 2022 Apr; 62(4):486-493. PubMed ID: 34608640
[TBL] [Abstract][Full Text] [Related]
38. New therapeutic agents marketed in 1993.
Hussar DA
Pa Med; 1994 May; 97(5):12-7. PubMed ID: 8036027
[TBL] [Abstract][Full Text] [Related]
39. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009.
Outterson K; Powers JH; Seoane-Vazquez E; Rodriguez-Monguio R; Kesselheim AS
J Law Med Ethics; 2013; 41(3):688-96. PubMed ID: 24088160
[TBL] [Abstract][Full Text] [Related]
40. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
